​

Neurogene Stock (NASDAQ:NGNE)

ForecastOwnershipFinancialsChart
Neurogene by TradingView

Previous Close

$29.89

52W Range

$6.88 - $74.49

50D Avg

$22.49

200D Avg

$18.65

Market Cap

$457.56M

Avg Vol (3M)

$178.63K

Beta

1.59

Div Yield

-

NGNE Company Profile

Neurogene Inc. develops life-changing genetic medicines for patients and their families affected by neurological diseases. Its product candidate includes NGN-401, an investigational AAV9 gene therapy for the treatment of Rett syndrome; and NGN-101 to treat neuronal ceroid lipofuscinosis subtype 5 batten disease. The company is headquartered in New York, New York.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

107

IPO Date

Mar 07, 2014

Website

NGNE Performance

NGNE Financial Summary

Dec 24Dec 23Dec 22
Revenue---
Operating Income$-82.61M$-55.58M$-56.52M
Net Income$-75.14M$-36.32M$-55.19M
EBITDA$-82.61M$-52.29M$-51.99M
Basic EPS-$-2.83$-4.30
Diluted EPS-$-2.83$-4.30

Fiscal year ends in Dec 24 | Currency in USD

Peer Comparison

TickerCompany
FULCFulcrum Therapeutics, Inc.
FDMT4D Molecular Therapeutics, Inc.
MBXMBX Biosciences, Inc. Common Stock
ADCTADC Therapeutics S.A.
ENGNenGene Holdings Inc.
SLDBSolid Biosciences Inc.
RCKTRocket Pharmaceuticals, Inc.
OCGNOcugen, Inc.
ALMSAlumis Inc. Common Stock
INBXInhibrx Biosciences, Inc.